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Transformation mediated by RhoA requires activity of 
ROCK kinases
Erik Sahai*†, Toshimasa Ishizaki‡, Shuh Narumiya‡ and Richard Treisman*
Background: The Ras-related GTPase RhoA controls signalling processes
required for cytoskeletal reorganisation, transcriptional regulation, and
transformation. The ability of RhoA mutants to transform cells correlates not
with transcription but with their ability to bind ROCK-I, an effector kinase
involved in cytoskeletal reorganisation. We used a recently developed specific
ROCK inhibitor, Y-27632, and ROCK truncation mutants to investigate the role
of ROCK kinases in transcriptional activation and transformation. 
Results: In NIH3T3 cells, Y-27632 did not prevent the activation of serum
response factor, transcription of c-fos or cell cycle re-entry following serum
stimulation. Repeated treatment of NIH3T3 cells with Y-27632, however,
substantially disrupted their actin fibre network but did not affect their growth
rate. Y-27632 blocked focus formation by RhoA and its guanine-nucleotide
exchange factors Dbl and mNET1. It did not affect the growth rate of cells
transformed by Dbl and mNET1, but restored normal growth control at
confluence and prevented their growth in soft agar. Y-27632 also significantly
inhibited focus formation by Ras, but had no effect on the establishment or
maintenance of transformation by Src. Furthermore, it significantly inhibited
anchorage-independent growth of two out of four colorectal tumour cell lines.
Consistent with these data, a truncated ROCK derivative exhibited weak ability
to cooperate with activated Raf in focus formation assays. 
Conclusions: ROCK signalling is required for both the establishment and
maintenance of transformation by constitutive activation of RhoA, and
contributes to the Ras-transformed phenotype. These observations provide a
potential explanation for the requirement for Rho in Ras-mediated transformation.
Moreover, the inhibition of ROCK kinases may be of therapeutic use.
Background
The RhoA GTPase controls diverse cellular processes
ranging from cytoskeletal reorganisation to transcription.
Many studies have demonstrated the involvement of
RhoA signalling in cell cycle progression and transforma-
tion. Activated forms of the Rho family GTPases RhoA
and Rac synergise strongly with Raf in transformation
assays, and interfering forms of these GTPases inhibit Ras
transformation; in addition, Rho protein guanine-
nucleotide exchange factors (GEFs) exhibit potent trans-
forming activity in vitro (see [1] for review). Activated Rho
can induce DNA synthesis in Swiss 3T3 cells, and Rho sig-
nalling has also been implicated in the degradation of the
cyclin-dependent kinase (CDK) inhibitors p21 and p27
during cell cycle re-entry and progression in response to
activated Ras [2–5]. The relationship between these obser-
vations and transformation, however, remains unclear. 
As is the case for other small GTPases, GTP-bound RhoA
acts by regulating the activity of effector proteins. Numer-
ous RhoA effectors have been identified, including at least
three families of protein kinases, the ROCKs, PRKs and
Citron kinase [1,6]. We previously used RhoA effector-loop
mutants, which are selectively defective in their interac-
tion with different effectors, to investigate the relationship
between these effectors and RhoA-controlled processes.
We found that transformation by activated RhoA mutants
correlated with their ability to bind ROCK kinases rather
than to potentiate transcriptional activation by serum
response factor (SRF) [7]. However, ROCK∆3, an ‘acti-
vated’ ROCK derivative, whose expression is sufficient to
induce aberrant rearrangement of the actin cytoskeleton,
remained inactive in the focus formation assay [7].
A pyridine-derived smooth muscle relaxant, Y-27632,
which can be specifically photo-crosslinked to ROCKs in
cell extracts, has recently been identified [8]. This com-
pound exhibits selectivity for ROCK in vitro and does not
inhibit other kinases tested, including both Rho effectors,
such as PRK1/PKN and Citron kinase, and others including
protein kinase C and protein kinase A [6,8] (T.I. and S.N.,
unpublished observations). Y-27632 inhibits processes 
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previously shown to be ROCK-dependent in vivo, such as
stress fibre bundling and focal adhesion assembly [8–12],
Na+/H+ exchange [13,14] and invasion of MM1 tumour
cells [15]. Here, we have used Y-27632 and additional
ROCK truncation mutants to investigate the role of ROCK
in the establishment and maintenance of transformation.
Our results show that in NIH3T3 cells ROCK activity is
selectively required for both establishment and mainte-
nance of transformation by RhoA and its GEFs Dbl and
mNET1, but not for transformation by Src, or for normal
growth control in nontransformed NIH3T3 cells. 
Results
Chronic treatment with Y-27632 disrupts the cytoskeleton
We first used staining with TRITC–phalloidin to assess the
effect of repeated treatment with Y-27632 on the actin
cytoskeleton of NIH3T3 cells (Figure 1a). In agreement
with a previous study in HeLa cells [8], we found that
treatment of cells growing in 5% serum with 10 µM 
Y-27632 was sufficient to substantially disrupt the actin
fibre network within 30 minutes. This effect persisted for
several hours, although substantial recovery of the
cytoskeleton was apparent after 24 hours (Figure 1a).
Although re-addition of Y-27632 at this time induced
similar changes to those observed following the initial treat-
ment (Figure 1a), repeated treatment with Y-27632 did not
affect the cells’ growth properties, as will be described
below. Cells maintained in 0.5% serum exhibited similar
cytoskeletal changes upon Y-27632 administration
(Figure 1b) and, as in HeLa cells, this treatment prevented
the induction of stress fibres by the activated Rho mutant,
RhoA.V14 (Figure 1c). Given that 2 µM Y-27632 had only
limited effects whereas 25 µM Y-27632 slightly impaired
cell growth (data not shown), we used daily administration
of 10 µM Y-27632 in the experiments presented below. 
Y-27632 does not inhibit signalling to SRF or to mitogen-
activated protein kinases 
Studies using RhoA effector-loop mutants and ROCK
overexpression suggested that, although deregulated
ROCK is able to activate SRF weakly, it is not required
for serum-induced signalling to SRF [7]. We used RNase
protection assays to test whether Y-27632 treatment
impaired serum induction of either a transfected SRF-con-
trolled reporter plasmid, 3D.AFosHA, or the endogenous
c-fos gene. Activation of neither gene by serum was pre-
vented, although activation of the SRF reporter gene was
somewhat reduced (Figure 2a). We also tested the effect
of Y-27632 treatment on the induction of SRF activity
using a microinjection assay. Y-27632 had no effect on the
activation of SRF induced by serum or the activated
Cdc42 mutant Cdc42.V12, but slightly reduced SRF activ-
ity induced by lysophosphatidic acid (LPA) in this assay
(Figure 2b). We did not evaluate the effect of Y-27632 on
RhoA.V14-induced SRF activity in these assays because
Y-27632 interfered with the synthesis or accumulation of
RhoA.V14 expressed from microinjected plasmids
although immunoblotting experiments showed that
inhibitor treatment did not affect endogenous RhoA levels
(data not shown).
We used immunoblotting experiments to monitor the
effects of Y-27632 on the activation of cellular mitogen-
activated protein (MAP) kinase pathways. Neither the
magnitude nor the kinetics of serum-induced activation of
the MAP kinase ERK2 were affected by 10 µM Y-27632
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Figure 1
The effect of Y-27632 on the actin
cytoskeleton. (a) NIH3T3 cells maintained in
5% serum (FCS) were treated with 10 µM 
Y-27632 for the indicated times; where
samples are labelled with two time points, this
indicates the effect of treatment for 24 h
followed by the subsequent readdition of
inhibitor for the time indicated. (b) NIH3T3
cells maintained in 0.5% serum were treated
with 10 µM Y-27632 for 2 h or left untreated.
(c) NIH3T3 cells maintained in 0.5% serum
for 24 h were microinjected with a RhoA.V14
expression plasmid (injected cells are
indicated with arrowheads) and incubated for
3 h, after which time they were either left
untreated or treated with Y-27632 for a
further 2 h, as indicated. The cells were fixed
and filamentous actin (F-actin) visualised
using TRITC–phalloidin. 
(a) 5% FCS + Y-27632
(b) 0.5% FCS
30 min 2 h 24 hUntreated
48 h24 h + 30 min 24 h + 2 h 24 h + 24 h
+ Y-27632Untreated
(c) 0.5% FCS + RhoA.V14
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Untreated + Y-27632
24 h untreated
48 h untreated
(Figure 2c). Similarly, the activation of the MAP kinase
JNK by stress stimuli was unaffected by 10 µM Y-27632
(Figure 2d). Taken together, these data show that ROCK
activity is not required for serum-induced signalling to
MAP kinase pathways, SRF or c-fos.
Y-27632 does not inhibit cell cycle re-entry or progression
We next examined the effects of Y-27632 on cell cycle re-
entry and progression. Y-27632 treatment did not prevent
re-entry of quiescent NIH3T3 cells into the cell cycle, as
assessed by measuring the incorporation of bromo-
deoxyuridine (BrdU) 20 hours after serum stimulation
(data not shown). Pulse-labelling experiments showed
that Y-27632 treatment did not significantly affect the
kinetics of entry into S phase, which commenced some
12 hours after serum stimulation (Figure 3a), nor did it
affect serum-induced changes in p27 and p21 levels
(Figure 3b). Although the Rho effector Citron kinase is
involved in cytokinesis, 10 µM Y-27632 did not affect the
proliferation rate of subconfluent NIH3T3 cells main-
tained in 5% serum, indicating that Citron kinase must be
unaffected (Figure 3c). These data establish that repeated
Y-27632 treatments do not affect cell cycle re-entry and
progression by nontransformed NIH3T3 cells. 
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The effect of Y-27632 on nuclear signalling. (a) NIH3T3 cells were
transfected with the SRF reporter plasmid 3D.AFosHA, maintained in
0.5% serum for 40 h and stimulated with 15% serum (FCS) for the
times indicated. Where indicated, 10 µM Y-27632 was added 30 min
before stimulation. RNase protection assays were used to analyse
FosHA, mouse c-fos and GAPDH mRNA levels; c-fos and FosHA
mRNA levels normalised to those of GAPDH are shown numerically at
the bottom. After 30 min, the serum-induced FosHA mRNA level was
75% of that measured in untreated cells (standard deviation, 24%;
n = 5). (b) NIH3T3 cells maintained in 0.5% serum were microinjected
with the 3D.AFosHA reporter plasmid and stimulated with either 15%
serum or 10 µM LPA or by co-injection of the Cdc42.V12 expression
plasmid. (c) Cells were stimulated as in (a) and cell lysates were
analysed by SDS–PAGE and immunoblotting for ERK2;
phosphorylated ERK2 (ERK2–P) is indicated. (d) NIH3T3 cells were
maintained in 0.5% serum for 24 h prior to stimulation with 50 ng/ml
anisomycin (Aniso) or ultraviolet radiation (UV); 10 µM Y-27632 was
added to samples 30 min before stimulation and total cell lysates were
analysed by immunoblotting for phosphorylated JNK (JNK–P).
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The involvement of ROCK in focus formation
We next used focus formation assays to assess the effect
of Y-27632 on transformation by different oncogenes.
RhoA.V14 is weakly active in this assay, but cooperates
with the activated Raf protein ∆NRaf; in both cases
transformation was strongly inhibited by Y-27632
(Figure 4a; Table 1). The inhibitor also completely pre-
vented focus formation induced by oncogenic forms of
two RhoGEFs, Dbl and mNet1, and substantially inhib-
ited focus formation induced by RasR12, an activated
Ras protein. In contrast, Y-27632 had no effect on focus
formation induced by v-Src (Figure 4a; Table 1). These
data indicate that Y-27632 does not non-specifically
inhibit focus formation per se but selectively inhibits
transformation by RhoA and its GEFs.
Ras effector-loop mutants able to activate either only 
Raf-1, Ral guanine-nucleotide dissociation stimulator
(RalGDS) or only phosphatidylinositol 3-kinase (PI 
3-kinase) are not transforming when tested alone, but
cooperate to cause transformation [16]. The low numbers
of foci produced in our cells by these mutant Ras proteins
alone or in combination, however, precluded their use in
assessing the potential role of ROCK in focus formation
(data not shown). We therefore examined the effects of 
Y-27632 on transformation by combinations of signalling
molecules known to mediate Ras signalling. Transforma-
tion by ∆NRaf and an activated form of the catalytic
subunit of PI 3-kinase, p110K→E, was substantially inhib-
ited by Y-27632 (Table 1). Although Rac1 is a PI 3-kinase
target, Y-27632 had no significant effect on cooperation
between activated Rac, Rac1.V12, and ∆NRaf in focus for-
mation assays, suggesting that PI 3-kinase but not Rac1
acts upstream of ROCK in transformation by Ras
(Table 1; also see Discussion). 
Together with our previous effector-loop mutant data [7],
these results strongly implicate ROCK in transformation.
We previously found that ROCK∆3, a ROCK deletion
derivative that induces gross disturbances in the actin
fibre network, was inactive in focus formation [7].
Recently, however, the ROCK mutant ROCK∆4, which
is less active in cytoskeletal rearrangement, was found to
substitute for active RhoA in invasion by MM1 tumour
cells [15]. We therefore tested whether ROCK∆4 could
cooperate with activated Raf in transformation. In con-
trast to ROCK∆3, this ROCK truncation mutant exhib-
ited weak but significant focus formation activity in
NIH3T3 cells, providing direct evidence that deregu-
lated ROCK activity can promote transformation
(Figure 4c). 
Y-27632 treatment restores normal growth control to cells
transformed with RhoAGEFs or H-Ras
The data presented above demonstrate that Y-27632
inhibits the establishment of transformation by activated
forms of RhoA, RhoAGEFs and H-Ras, but do not
address the potential relevance of ROCK signalling for
the maintenance of the transformed state. To investigate
the latter, we derived cell lines from foci transformed by
RhoA, Dbl, mNET1∆N, H-RasR12 and v-Src and exam-
ined the effects of Y-27632 on their growth properties.
Each of eight lines examined had doubling times up to
20% shorter than the parental NIH3T3 cells, but their
growth rates were unaffected by Y-27632 treatment (data
not shown). 
We tested whether Y-27632 would prevent the formation of
secondary foci upon reseeding of transformed cells among
nontransformed NIH3T3 cells. One thousand transformed
cells were plated with 30,000 parental nontransformed
Figure 3
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The effect of Y-27632 on cell cycle progression and subconfluent
growth. (a) NIH3T3 cells maintained in 0.5% serum for 48 h were
stimulated with 15% serum. Where indicated, 10 µM Y-27632 was
added 30 min before serum addition. Cells in S phase were detected
at various times after stimulation by measuring BrdU incorporation
following a 2 h BrdU pulse. (b) Immunoblot analysis of p21 and p27
levels 14 h after cells were serum-stimulated, as described in (a).
(c) Subconfluent NIH3T3 cells, maintained in 5% serum with or
without daily addition of 10 µM Y-27632, were counted daily.
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NIH3T3 cells in 35 mm dishes, and maintained for nine
days in 5% serum with or without 10 µM Y-27632. Cell
lines transformed by Dbl, mNET1∆N, or H-RasR12
formed between 10 and 72 foci per thousand cells, whereas
two Src-transformed cell lines formed more than 100 foci
per thousand cells. In contrast, RhoA.V14-transformed cells
formed secondary foci only very inefficiently. Thus, 
Y-27632 treatment blocked the ability of cells transformed
by Dbl, mNET1∆N, H-RasR12 or RhoA.V14 to form sec-
ondary foci, but had no effect on Src-transformed cells
(Figure 4b; Table 2). The RhoA-transformed cell lines
were not studied further. 
Although the inhibition of secondary focus formation by
Y-27632 is consistent with the restoration of cell cycle
control by contact inhibition, it might also arise as a conse-
quence of increased apoptosis at high cell density. We
therefore tested directly whether Y-27632 treatment
restores cell cycle exit at confluence. Transformed cells
were seeded in 35 mm dishes and maintained in 5%
serum for eight days either in the absence or presence of
10 µM Y-27632. The cell densities reached by each cell
line were then compared (Figure 5a), and the proportion
in cycle estimated by pulse-labelling with BrdU for the
24 hours prior to harvest (Figure 5b). Parental NIH3T3
cells grew to about 650 cells per mm2, with approximately
10% labelling with BrdU and, as expected, 
Y-27632 treatment had no effect on either value
(Figure 5). All the transformed cell lines grew to signifi-
cantly higher densities than the nontransformed parental
cells (Figure 5a), and, at these densities, retained a greater
proportion of BrdU-positive cells (Figure 5b). In the pres-
ence of Y-27632, both Dbl and mNET1∆N cell lines grew
to a density similar to that of the parental NIH3T3 cells,
and the proportion of cells in cycle was reduced in parallel
(Figure 5b). In striking contrast, Y-27632 had no effect on
the saturation density or cycling of the two Src cell lines
(Figure 5a,b). In the case of the Ras-transformed cells,
however, Y-27632 treatment caused a substantial reduc-
tion in saturation density, but the number of cells in cycle
at this density remained substantially greater than for the
parental cells (Figure 5a,b). Taken together, these results
show that Y-27632 restores growth control to cells trans-
formed by RhoAGEFs but not to cells transformed by Src. 
Figure 4
The involvement of ROCK in transformation. (a) NIH3T3 cells were
transfected with the indicated expression plasmids and maintained in
5% serum for 14 days with or without daily addition of 10 µM 
Y-27632. (b) Cells from the indicated cell lines were seeded among
nontransformed NIH3T3 cells and maintained in 5% serum for 9 days
with or without daily addition of 10 µM Y-27632. (c) NIH3T3 cells
were transfected with the indicated ROCK expression plasmids with
and without a plasmid encoding activated Raf (∆NRaf), as indicated,
and maintained in 5% serum for 14 days. The asterisk indicates
significance compared to mock transfection at p = 0.007, significance
compared to the ∆NRaf at p = 0.02 (Student t test). 
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Table 1
Focus formation assays.
Plasmid Number of foci per 0.5 µg DNA
No inhibitor + 10 µM Y-27632
Control (4) 0.4 (0.5) 0
∆NRaf (2) 1 (1.4) 0
RhoA.V14 (3) 6 (2) 0.3* (0.6)
RhoA.V14 + ∆NRaf (3) 18 (8.1) 2.6 (2.8)
Dbl (3) 5.7 (0.5) 0*
mNET1∆N (4) 30 (12.8) 0*
H-RasR12 (3) 208 (39) 60* (18)
v-Src (3) 465 (96) 465 (120)
Rac1.V12 (6) 1.4 (1.5) 0
Rac1.V12 + ∆NRaf (6) 27.5 (7.9) 21 (12.7)
p110K→E (1) 2 1
p110K→E + ∆NRaf (2) 14 (2.8) 3 (1.4)
NIH3T3 cells were transiently transfected with the indicated
expression plasmids and maintained in 5% serum with or without daily
addition of 10 µM Y-27632. The medium was changed every two days.
After 14 days, cells were stained with crystal violet and foci larger
than 1.5 mm in diameter were counted. The number of independent
experiments and standard deviations are indicated in parentheses next
to plasmid names and average number of foci, respectively. An asterisk
(*) indicates significance at 1% level (Student t test).
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The effect of Y-27632 on transformed cell morphology
RhoA has been implicated in the formation of stress
fibres, focal adhesions, and cadherin-mediated cell–cell
adhesion. We therefore examined the effect of Y-27632 on
the cytoskeleton of both parental and transformed
NIH3T3 cells to determine whether its effects on growth
control correlated with its effect on any aspects of cell
morphology. NIH3T3 cells grown in 5% serum with
10 µM Y-27632 exhibited reduced size and abundance of
focal adhesions, as judged by immunostaining for paxillin
and integrin β1; their predominantly peripheral location
reflected the disorganisation of actin fibres (Figure 6a).
Similar effects were observed in the transformed cell lines
(data not shown). Immunoblotting with anti-phosphotyro-
sine antibodies showed that Y-27632 treatment affected
neither the basal level of tyrosine phosphorylation nor that
induced by serum-stimulation of starved cells. Moreover,
Y-27632 did not affect the spectrum of tyrosine-phospho-
rylated proteins detectable at confluence in the various
transformed cell lines (data not shown). The cadherin-
associated protein β-catenin is localised to sites of cell–cell
contact, which are distinct from focal adhesions (Figure
6a). Treatment with 10 µM Y-27632 reduced the level of
β-catenin staining at these sites, but this occurred both in
the parental NIH3T3 cells and the transformed cell lines
with the exception of those transformed by Src, in which
β-catenin did not localise to sites of cell contact (Figure 6a
and data not shown). 
We also examined the effect of Y-27632 on filamentous
actin (F-actin) structures in normal and transformed
NIH3T3 cells. The morphology of the transformed cell
lines was markedly different from that of the parental
NIH3T3 cells: Dbl- and mNET1∆N-transformed cells had
large lamellipodia-like structures with relatively few actin
fibres, which were not sensitive to Y-27632 (Figure 6b;
compare with Figure 1a). In contrast, both the H-RasR12-
and Src-transformed cells had fewer actin fibres than the
parental cells, and the Src-transformed cells also possessed
F-actin patches; however, neither structure was sensitive to
Y-27632. Thus, the effects of Y-27632 on cell cycle control
cannot be correlated with gross effects on F-actin struc-
tures or focal adhesions.
Inhibition of anchorage-independent growth by Y-27632
Finally, we tested whether Y-27632 treatment could
inhibit anchorage-independent growth. Colony formation
in soft agar by parental NIH3T3 cells was very inefficient
and was insensitive to Y-27632. In contrast, the cells trans-
formed by Dbl, mNET1∆N, or H-RasR12 grew in soft
Figure 5
Y-27632 restores growth control to transformed cell lines. 30,000 cells
of the indicated cell line were seeded in 35 mm wells and maintained in
5% serum for eight days with or without 10 µM Y-27632; fresh 
Y-27632 was added daily and the medium was changed every two
days. 24 h prior to harvesting BrdU was added to the medium and
upon harvesting both the total number of cells per mm2 and the
percentage of BrdU-positive cells were calculated. Black and grey bars
represent cells treated with and without 10 µM Y-27632, respectively.
The data shown are the average of two or three independent
experiments ± half range or standard error. (a) Effect of Y-27632
treatment on total cell number per mm2. (b) Effect of Y-27632
treatment on the percentage of BrdU-labelled cells at confluence.
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Table 2
Secondary focus formation assays.
Cell line Number of foci per 1,000 cells
No inhibitor + 10 µM Y-27632
NIH3T3 (3) 0 0
RhoA-2 (3) 7 (6.5) 0
RhoA-4 (3) 1 (1) 0
Dbl-d (3) 72 (15) 3.6 (4.7)
Dbl-e (3) 10 (1.5) 0
mNET1-d (3) 32 (22) 0
mNET1-e (3) 23 (12) 0.7 (1.2)
Ras-2 (3) 36 (22) 1.3 (1.5)
Ras-4 (3) 28 (19) 2 (3.5)
Src-1 (2) 121 (44) 126 (44)
Src-4 (2) 316 (63) 322 (105)
One thousand cells from each of the indicated cells lines were plated
among 30,000 nontransformed parental NIH3T3 cells and maintained
in 5% serum with or without daily addition of 10 µM Y-27632. The
medium was changed every two days. After 9 days, cells were stained
with crystal violet and foci larger then 1 mm in diameter were counted.
The number of independent experiments and standard deviations (or
half range) are indicated in parentheses next to plasmid names and
average number of foci, respectively.
agar. Colony formation by the Dbl- and mNET1∆N-trans-
formed cell lines was substantially inhibited by Y-27632,
however. Both Ras-transformed cell lines were also sensi-
tive to Y-27632, although Ras-2 cells were only partially
affected. Colony formation by three Src-transformed cell
lines tested was both efficient and not significantly inhib-
ited by Y-27632 (Table 3). 
Taken together, our data suggest that deregulation of
ROCK activity mediates both loss of contact inhibition and
anchorage-independent growth in NIH3T3 cells trans-
formed in vitro by RhoAGEFs or oncogenic H-Ras. To test
whether cell lines selected for altered growth properties in
vivo also exhibited dependence on ROCK activity, we
tested whether Y-27632 would inhibit anchorage-indepen-
dent growth of four human epithelial cell lines derived
from colorectal tumours, each of which contains an activat-
ing Ras mutation. Of the cell lines tested, HCT15,
HCT116 and LS174T cells formed colonies within 17
days, while SW620 cells did not. Treatment with 10 µM 
Y-27632 dramatically reduced the ability of HCT116 and
LS174T cells to grow in soft agar but had little effect on
the growth of HCT15 cells (Table 3). Y-27632 did not
affect the growth rate of any of these cell lines. Moreover,
as with the NIH3T3-derived cell lines, although Y-27632
treatment brought about changes in the distribution of 
cadherin, β-catenin and paxillin, these changes occurred
regardless of whether cell growth was affected by the com-
pound (data not shown). These data suggest that ROCK
activity can also be important for the transformed pheno-
type of cells selected during tumorigenesis in vivo.
Discussion
In this work, we investigated the role of ROCK kinases in
transformation by RhoA and its regulators, using a specific
ROCK inhibitor, Y-27632, and truncated derivatives of
ROCK. We found that Y-27632 had no effect on the
growth of nontransformed cells but selectively blocked
transformation by RhoA, its GEFs and Ras. Contact inhi-
bition in RhoGEF-transformed cells was restored by treat-
ment with Y-27632, which also inhibited the
anchorage-independent growth of RhoGEF-transformed
cells and two epithelial tumour cell lines. Moreover, a
truncated ROCK derivative, ROCK∆4, exhibited weak
activity in focus-formation assays with activated Raf.
These results strongly suggest that ROCK activity is
important for the establishment and maintenance of trans-
formation, and are consistent with our previous demon-
stration that transformation by activated RhoA
effector-loop mutants correlates with their ability to bind
ROCK [7]. Although we cannot exclude the possibility
that Y-27632 acts by inhibiting targets other than ROCK,
several lines of evidence argue that this is not the case.
Previous studies have demonstrated the selective inhibi-
tion of ROCK-dependent processes by Y-27632, including
the formation of focal adhesions and stress fibres, Na+/H+
exchange, and invasion by MM1 tumour cells [8,13–15].
Biochemical studies have shown that, at the concentration
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Figure 6
The effect of Y-27632 on the cytoskeleton.
(a) NIH3T3 cells maintained in 5% serum
were fixed and stained for paxillin (red) and 
F-actin (coumarin–phalloidin; green; left
panels) or integrin β1 (green) and β-catenin
(red; right panels). Where indicated, cells
were treated with Y-27632 30 min before
fixation. (b) Transformed NIH3T3 cell lines
maintained in 5% serum were stained with
TRITC–phalloidin to visualise F-actin. Where
indicated, cells were treated with Y-27632 
30 min before fixation.
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used in our experiments, Y-27632 does not inhibit other
RhoA effector kinases such as Citron kinase and PKN
[6,8] (T.I. and S.N., unpublished observations), and that
Y-27632 can be specifically photo-crosslinked to ROCK in
cell extracts [8]. Finally, we found that Y-27632 treatment
did not impair activation of the ERK and JNK MAP
kinase pathways. 
Our studies with RhoA effector-loop mutants suggested
that ROCK binding is not required for SRF activation
[7]. Although overexpression of truncated ROCK pro-
teins does potentiate SRF activity [7,17], this is RhoA-
dependent, and we therefore think that it arises either as
a result of aberrant cytoskeletal rearrangements or
through cooperation with other Rho effectors [7]. The
failure of Y-27632 to significantly impair SRF activation
at concentrations sufficient to disrupt the cytoskeleton
suggests that ROCK is not an obligatory intermediate in
signalling to SRF, but may affect the efficiency of signal
transmission. Activity of the c-fos promoter is dependent
on both SRF and additional signal-regulated transcription
factors including the ternary complex factors, which are
regulated by MAP kinases. Y-27632 treatment did not
inhibit either ERK activation or c-fos induction following
serum stimulation.
Cell cycle progression is dependent on adhesion to matrix
and is inhibited by cell–cell contact (for recent reviews, see
[18,19]). Our data suggest that constitutive RhoA activation
either mimics signals generated by cell anchorage or
inhibits those occurring at confluence. Although the nature
of such signals remains unclear, ROCK is intimately
involved in these processes. ROCK is required for signal-
induced assembly of focal adhesion complexes in several
cell types [9–12,20], and has also been implicated in Rho-
dependent focal adhesion assembly following
integrin–fibronectin interaction, possibly through its effects
on the NHE1 Na+/H+ exchanger [13,14,21]. In addition,
RhoA also controls cadherin-mediated cell–cell adhesion
[22–25] and insoluble matrix assembly [26,27]. Given that
Src-family kinases are associated with focal adhesions, the
lack of sensitivity of Src transformation to Y-27632 is con-
sistent with their acting downstream of ROCK in transfor-
mation. We were unable to identify Y-27632-induced
alterations in tyrosine phosphorylation, F-actin structures or
β-catenin staining specific to transformed cells sensitive to
the compound, although this may merely reflect the low
resolution of our methods. It will be interesting to examine
whether transformation alters the phosphorylation state of
ROCK substrates such as myosin light chain (MLC) [11],
the MLC phosphatase [28], the Na+/H+ exchanger NHE1
[14], and ezrin–radixin–moesin (ERM) proteins [29]. 
Studies of the role of Rho signalling in cell cycle transit
have revealed links between Rho-mediated signalling and
accumulation of the CDK inhibitors p21 and p27 [2–5]. In
Swiss 3T3 cells expressing activated Ras, RhoA signalling
inhibits the accumulation of p21 [3]. In contrast, in our 
Y-27632-sensitive transformed cells, whether transformed
by RhoGEFs or Ras, p21 levels were either unchanged or
actually decreased following the inhibition of ROCK
(E.S., unpublished observations). We also found that the
inhibition of ROCK by Y-27632 did not affect changes in
p21 and p27 levels occurring during cell cycle re-entry of
serum-stimulated NIH3T3 cells. Further work is neces-
sary to clarify the connection between RhoA signalling,
CDK inhibitor accumulation and transformation.
Both RhoA and Rac1 are required for transformation by
Ras (reviewed in [1]), but although Y-27632 significantly
inhibited focus formation by activated Ras, we were
unable to determine whether a specific Ras effector
pathway is involved. Focus formation assays with acti-
vated forms of PI 3-kinase and Rac1 suggested that
ROCK activity is specifically required for transformation
by PI 3-kinase but not by Rac1; PI 3-kinase may thus
control Rho activity independently of Rac1, as suggested
by others [30,31]. Curiously, cells transformed by Ras, but
not those transformed by NET1 or Dbl, failed to effi-
ciently exit the cell cycle at confluence in the presence of
Y-27632; preliminary experiments, in which the TUNEL
technique was used to monitor DNA fragmentation, 
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Table 3
Y-27632 inhibits anchorage-independent growth.
Cell line Colony formation
No inhibitor + Y-27632
Expt 1 Expt 2 Expt 1 Expt 2
NIH3T3 5 0 0 5
Dbl-d 63 65 0 5
Dbl-e 33 4 2 0
mNET1-d 15 71 2 10
mNET1-e 20 18 5 5
Ras-2 49 46 20 19
Ras-4 24 17 4 6
Src-1 420 143 421 80
Src-4 409 487 452 240
NIH3T3 0 0 0 1
Src-1 308 312 323 319
Src-2 155 140 140 72
SW620 0 0 0 0
HCT15 316 135 207 142
HCT116 39 57 0 0
LS174T 296 85 56 11
Five thousand parental NIH3T3 cells or transformed NIH3T3 cell lines
were maintained in suspension in soft agar in DME/10% serum with or
without 18 µM Y-27632; medium and inhibitor were changed three
times per week. Human colorectal tumour cells (1000 cells per cell
line) were maintained in suspension in soft agar in DME/10% serum
with or without daily administration of Y-27632 to 10 µM. Colonies
visible to the naked eye (~100 cells) after neutral-red staining were
counted after 24 days (NIH3T3 derivatives) or 18 days (tumour cell
lines). The results of two independent experiments for each group of
cell lines are shown.
indicate that these cells exhibit increased apoptosis (E.S.,
unpublished observations). 
It is intriguing that Y-27632 also significantly inhibited the
anchorage-independent growth of two out of the four
epithelial tumour cell lines examined. The altered growth
properties of these cells are at least partly the result of
mutational changes selected in vivo, so our results demon-
strate that the involvement of RhoA-controlled signalling
in transformation is not limited only to in vitro models
using cultured cells. Moreover, a recent study indicated
that ROCK may also play a role in Rho-dependent tumour
cell invasion [15]. It is therefore likely that at least some
tumour cells may exhibit sensitivity to inhibition of
ROCK kinases in vivo, and drugs that target the ROCK
kinases might be useful as anti-tumour agents.
Conclusions
The ROCK family of RhoA effector kinases is required for
the establishment and maintenance of transformation,
both in RhoA-mediated transformation of NIH3T3 fibro-
blasts and in a subset of cell lines derived from colorectal
tumours. The failure of Y-27632 to inhibit the growth of
normal nontransformed cells, coupled with its ability to
restore growth control at confluence, suggests that consti-
tutive Rho activation may contribute to transformation
either by mimicking growth promoting signals generated
by cell anchorage or by blocking growth-inhibitory signals
induced by confluence. Use of inhibitors of ROCK activ-
ity may thus provide novel therapeutic strategies. 
Materials and methods
Cell culture, extract preparation and analyses
NIH3T3 and human colorectal tumour cell lines were gifts from Chris
Marshall. Cells were routinely maintained in DMEM with donor calf
serum (DCS; Gibco). Y-27632 was from Yoshitomi Pharmaceutical
Industries Ltd. Cells were stimulated with 10 µM lysophosphatidic
acid (Sigma), 15% DCS, 100 ng/ml anisomycin or UV irradiation, as
described [32]. Immunoblotting was by standard methods. Antibod-
ies were as follows: pan-ERK, Transduction Laboratories; phospho-
JNK, Santa Cruz; p21, Santa Cruz; p27, Santa Cruz; β-catenin (VB2)
and integrin β1 (9EG7), gifts from Fiona Watt, ICRF; paxillin, Trans-
duction Laboratories. TRITC–phalloidin was from Sigma. NIH3T3
cells were transfected using DEAE dextran or lipofectamine; RNase
protection assays were performed as described [32]. Microinjection
assays were performed as described [7]; Y-27632 was added imme-
diately after injection.
Immunofluorescence
Cells were fixed with fresh 4% formaldehyde in PBS for 15 min followed
by extraction in 0.3% Triton X-100, except for focal adhesion staining
where the cells were simultaneously fixed and permeablised using 4%
formaldehyde and 0.2% Triton X-100. Antibodies were diluted 1:100 in
PBS + 8% calf serum and the cells were washed four times in PBS
after antibody incubations and prior to mounting. Images were obtained
using a Zeiss Axiovert microscope and Smart Capture system (Vysis)
and processed as PICT files using Adobe Photoshop 3.0.
Focus formation assays
Focus formation assays were performed as described previously [7],
except that following transfection cells were split into two 6 cm dishes,
one of which was treated with 10 µM Y-27632 daily. For secondary
focus formation assays, 1000 cells were plated into 30,000 parental
NIH3T3 cells in a 35 mm well. The cultures were maintained for 10 days
in DMEM + 5% DCS, which was changed three times a week; 10 µM
Y-27632 was added daily. Cells were harvested by washing once with
PBSA, followed by staining with 0.1% crystal violet (Sigma) in 10%
methanol and PBSA. Foci larger than 1 mm in diameter were counted.
Cell cycle assays
Following maintenance in 0.5% serum for 48–60 h, NIH3T3 cells were
stimulated with 15% DCS; p21 and p27 levels were analysed by
immunoblotting and cells in S phase were detected by 2 h pulse-labelling
with BrdU (Boehringer Mannheim). The growth rate of subconfluent cells
maintained in 5% serum was measured by counting the number of cells
daily over a 4 day period. To evaluate cell cycle exit at confluence approx-
imately 30,000 cells were seeded in a 35 mm well, maintained in 5%
serum and 10 µM Y-27632 for 8 days, and pulse-labelled with BrdU for
24 h prior to staining for BrdU and DNA (using Hoechst 33258).
Soft agar assays
Bottom agar (2ml; 0.9% ultra-pure LMP agarose (BRL life technology),
1 × DMEM, 10% DCS) was poured into a 35 mm well and allowed to
set. Either 1000 or 5000 cells were mixed with top agar (2 ml; 0.5%
LMP agarose, 1 × DMEM, 10% DCS) at 40°C and the mixture poured
onto the bottom agar. Cells were maintained for 21 days, with 200 µl of
DMEM + 10%DCS added three times per week. For visualisation,
colonies were incubated with 1 ml 0.01% neutral red (Sigma) in PBSA
for 1 h. Colonies visible to the naked eye (~100 cells) were counted.
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